EVX-V1

July 12, 2026: Evaxion A/S (NASDAQ: EVAX) presented new preclinical data for its cytomegalovirus (CMV) vaccine program EVX-V1 in a poster at the International Herpesvirus Workshop (IHW) 2026 in Montreal. EVX-V1 is a next-generation, multi-component CMV vaccine concept combining AI-discovered novel B-cell antigens and T-cell epitopes with AI-optimized versions of established CMV vaccine antigens, including an AI-optimized pre-fusion glycoprotein B (gB).

The company reported that newly identified AI-Immunology–discovered T-cell epitopes showed potential to improve control of acute infection, latency, and viral reactivation in CMV-infected mice. These findings are positioned as complementary to prior preclinical results cited in the release: novel B-cell antigens significantly reduced viral infection in models, and optimized structural B-cell antigens produced superior viral neutralization versus traditional gB.

Evaxion said the new data will guide antigen selection for a broadly protective CMV vaccine candidate; no regulatory filings or clinical trial timelines were provided.